4519 JP3519400000

Report

Delayed Japan Exchange - 09:10:09 2023-05-31 pm EDT
3800.00	JPY		+1.20%

05/29	Chugai Obtains Approval for FoundationOne Liquid CDx Cancer Genomic Profile to Be Used as a Companion Diagnostic for Novartis MET Inhibitor, Capmatinib	AQ
04/30	Chugai Pharmaceutical Completes Payment of Restricted Share Compensation	MT
04/28	Chugai Files for Additional Indication of Vabysmo for Macular Edema Associated with Retinal Vein Occlusion in Japan	AQ

Company

Business Summary

Chugai Pharmaceutical Co. Ltd specializes in the research, development, manufacturing and marketing of drugs especially for cancers (40.8% of net sales), bones and joints diseases treatment (18.4%), and kidney diseases (5.9%).

Net sales are distributed geographically as follows: Japan (74,3%), Switzerland (22,8%) and other (2,9%).

Number of employees : 7 771 people.

Sales per Business

	2021		2022		Delta
Pharmaceuticals	802 836.00	80.3%	1 039 250.00	82.5%	+29.45%
Royalties and Other	196 922.00	19.7%	128 784.00	10.2%	-34.6%
Other	-	-	91 915.00	7.3%	-
JPY in Million

Sales per region

	2021		2022		Delta
Japan	522 397.00	52.3%	657 273.00	37.7%	+25.82%
Overseas	27 144.00	2.7%	602 672.00	34.6%	+2120.28%
Switzerland	450 217.00	45%	482 736.00	27.7%	+7.22%
JPY in Million

Managers

Name	Title	Age	Since
Tatsuro Kosaka	Manager-Pharmaceutical Business Strategy Office	70	2000
Osamu Okuda	Manager-Life Cycle Management II	60	2008
Itagaki Toshiaki	CFO, Manager-Information Technology & Accounting	-	2018
Hisafumi Okabe	Senior Executive Officer & Head-Research	-	2018
Junichi Nezu	Executive Officer, GM-Research & Development	-	-
Yoko Kitagawa	Group Manager-Finance & Accounting	-	-
Shinji Hidaka	Executive Officer & General Manager-Sales	-	-
Shinya Unno	Head-Personnel, Legal & General Affairs	-	2020
Yasushi Ito, Dr.	Senior Executive Officer	66	2018
Toshihiko Komori	Executive Officer	-	2018

Members of the board

Name	Title	Age	Since
Tatsuro Kosaka	Manager-Pharmaceutical Business Strategy Office	70	2000
Masayuki Oku	Independent Outside Director	78	2015
Yoichiro Ichimaru	Independent Outside Director	74	2017
Mariko Momoi	Independent Outside Director	75	2020
Motoo Ueno	Managing Director	65	1997
Christoph Franz	Director	62	2017
William N. Anderson	Director	56	2019
James H. Sabry, Dr.	Director	64	2019
Osamu Okuda	Manager-Life Cycle Management II	60	2008

Equities

	Vote	Quantity	Free-Float		Company-owned shares		Total Float
Stock A	0.01	1,679,057,667	637,744,574	38.0%	33,925,348	2.0%	38.0%

Shareholders

Name	Equities	%
Roche Holding AG	1,005,670,000	59.9%
Nomura Asset Management Co., Ltd.	51,735,398	3.08%
Chugai Pharmaceutical Co., Ltd.	33,911,300	2.02%
William Blair Investment Management LLC	26,811,000	1.60%
Daiwa Asset Management Co. Ltd.	24,084,699	1.43%
Nikko Asset Management Co., Ltd.	24,059,700	1.43%
Wellington Management Co. LLP	19,086,044	1.14%
The Vanguard Group, Inc.	17,417,072	1.04%
Mitsubishi UFJ Kokusai Asset Management Co., Ltd.	12,198,800	0.73%
Harding Loevner LP	11,467,300	0.68%

Holdings

Name	Equities	%	Valuation
CHUGAI PHARMACEUTICAL CO., LTD (4519)	33,911,300	2.02%	872,656,099 USD
ONCOLYS BIOPHARMA INC. (4588)	456,600	2.62%	2,082,388 USD

Markets and indexes

- Prime

- Nikkei 225 /

Stock Exchange Codes


- Bloomberg Code :	4519:JP
- Reuters Code :	4519.T
- Datastream Code :

Company contact information

Chugai Pharmaceutical Co., Ltd
Nihonbashi Mitsui Tower 1-1 Nihonbashi-Muromachi 2-chome
JP-103-8324 Chuo-ku, Tokyo

Phone : +81 3 3281 6611
Fax : +81 3 3281 6607
web site : https://www.chugai-pharm.co.jp/english/ir

Brand Portfolio

In partnership with

Allbrands.markets

More brands of Chugai Pharmaceutical Co., Ltd

Analysis

The long-running crisis at Japan's Toshiba

CHUGAI PHARMACEUTICAL CO., LTD